Research Article
American Journal of BioMedicine
Volume 11, Issue 3, 04 August 2023, Pages 124-135 | http://dx.doi.org/10.18081/2333-5106/2023.11/124
Wei Chen*, Xinxin Giles, Xiaoyan Liu 1
Received 22 February 2023; Revised 25 May 2023; Accepted 20 June 2023; Published 04 August 2023
Abstract
The 12th leading cause of death in the United States is cirrhosis. Recent studies have shown that liver fibrosis is an ever-evolving process and that early cirrhosis may be reversible. One in three people with cirrhosis is unaware of their condition. The most well-known reasons for cirrhosis are viral hepatitis C, alcoholic liver sickness, and nonalcoholic steatohepatitis. The aim of the study is to compare the different therapeutic approaches to patients with liver cirrhosis due to the hepatitis C and ascites systemic meta‐analysis study. In this study, we looked through Embase, MEDLINE, Science Reference Record Extended, and preliminary registers until December 2022 to distinguish randomized clinical preliminaries in patients with cirrhosis because of hepatitis C and ascites. The study comprised 2344 revised articles. Roughly 30.3% of members got paracentesis in addition to liquid substitution. A transjugular intrahepatic portosystemic shunt was associated with a higher rate of ascites resolution at maximal follow-up (HR 5.22; 95% CrI 1.97 to 76.67) and adding aldosterone adversaries to paracentesis in addition to liquid substitution (HR 20.22; 95% CrI 4.03 to 434.91) contrasted with paracentesis in addition to liquid substitution (extremely low-sureness proof). In conclusion, in light of extremely low-assurance proof, transjugular intrahepatic portosystemic shunt and adding aldosterone adversaries to paracentesis in addition to liquid substitution might expand the goal of ascites contrasted with paracentesis in addition to liquid substitution.
Keywords:Ascites; Hepatitis C; Liver cirrhosis; Systemic meta-analysis
Copyright © 2023 Chen W et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
| 1. Scaglione S, Kliethermes S, Cao G, et al. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol 2015; 49:690-696. https://doi.org/10.1097/MCG.0000000000000208 |
||||
| 2. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383:1749-1761. https://doi.org/10.1016/S0140-6736(14)60121-5 |
||||
| 3. Arroyo V, Moreau R, Jalan R. Acute-on-Chronic Liver Failure. N Engl J Med 2020; 382:2137-2145. https://doi.org/10.1056/NEJMra1914900 |
||||
| 4. Arroyo V, Moreau R, Kamath PS, et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016; 2:16041. https://doi.org/10.1038/nrdp.2016.41 |
||||
| 5. Wadhawan M, Anand AC. Coffee and liver disease. J Clin Exp Hepatol 2016; 6(1):40-46. https://doi.org/10.1016/j.jceh.2016.02.003 |
||||
| 6. Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60(6):2008-2016. https://doi.org/10.1002/hep.27199 |
||||
| 7. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥ 10% is associated with improved hepatic fibrosis in patients with non-alcoholic steatohepatitis. Dig Dis Sci 2015; 60(4):1024-1030. https://doi.org/10.1007/s10620-014-3380-3 |
||||
| 8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69(2):406-460. https://doi.org/10.1016/j.jhep.2018.08.009 |
||||
| 9. Wadhawan M, Anand AC. Coffee and liver disease. J Clin Exp Hepatol 2016; 6(1):40-46. https://doi.org/10.1016/j.jceh.2016.02.003 |
||||
| 10. Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60(6):2008-2016. https://doi.org/10.1002/hep.27199 |
||||
| 11. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥ 10% is associated with improved hepatic fibrosis in patients with non-alcoholic steatohepatitis. Dig Dis Sci 2015; 60(4):1024-1030. https://doi.org/10.1007/s10620-014-3380-3 |
||||
| 12. Fukui H, Wiest R. Changes of Intestinal Functions in Liver Cirrhosis. Inflamm Intest Dis 2016; 1:24-40. https://doi.org/10.1159/000444436 |
||||
| 13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69(2):406-460. https://doi.org/10.1016/j.jhep.2018.08.009 |
||||
| 14. El-Bakaa HS, Al-Amranm FG, Nöth UA. Role of stem cells transplantation for patients with spinal cord injury: systematic meta-analysis. Journal of Population Therapeutics and Clinical Pharmacology 2023; 30(7):211-221. https://doi.org/10.47750/jptcp.2023.30.07.026 |
||||
| 15. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60(2):715-735. https://doi.org/10.1002/hep.27210 |
||||
| 16. Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4):1560-1599. https://doi.org/10.1002/hep.29800 |
||||
| 17. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:S45-S57. https://doi.org/10.1016/j.jhep.2014.07.027 |
||||
| 18. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60(2):715-735. https://doi.org/10.1002/hep.27210 |
||||
| 19. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416. https://doi.org/10.1056/NEJMoa1012912 |
||||
| 20. Best AF, Haozous EA, Berrington de Gonzalez A, et al. Premature mortality projections in the USA through 2030: a modelling study [published correction appears in Lancet Public Health 2018; 3(8):e364. https://doi.org/10.1016/S2468-2667(18)30114-2 |
||||
| 21. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53:96-105. https://doi.org/10.1002/hep.24018 |
||||
| 22. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51:1593-1602. https://doi.org/10.1002/hep.23567 |
||||
| 23. Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147:132-142.e4. | ||||
| 24. Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015; 49(8):690-696. https://doi.org/10.1097/MCG.0000000000000208 |
||||
| 25. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019; 156(1):254-272.e11. https://doi.org/10.1053/j.gastro.2018.08.063 |
||||
| 26. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383:1749-1761. https://doi.org/10.1016/S0140-6736(14)60121-5 |
||||
| 27. de Franchis R Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63:743-752. https://doi.org/10.1016/j.jhep.2015.05.022 |
||||
| 28. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51:454-462. https://doi.org/10.1002/hep.23312 |
||||
| 29. Calvaruso V, Cammà C, Di Marco V, et al. Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. J Viral Hepat 2010; 17:469-474. https://doi.org/10.1111/j.1365-2893.2009.01199.x |
||||
| 30. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105:1346-1353. https://doi.org/10.1038/ajg.2009.746 |
||||
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.